Co-Diagnostics files FDA 510(k) for flu and RSV PCR test

Co-Diagnostics has filed a Dual 510(k) premarket notification and a CLIA Waiver application with the FDA for its Co-Dx PCR Flu A/B & RSV multiplex test, aiming to enable decentralised point-of-care testing beyond traditional labs.

This Wire brief sits within Fusion42's coverage of Diagnostics.